Compare · BMRA vs ORKA
BMRA vs ORKA
Side-by-side comparison of Biomerica Inc. (BMRA) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BMRA and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $3.10B, about 458.1x BMRA ($6.8M).
- Over the past year, BMRA is down 42.3% and ORKA is up 482.9% - ORKA leads by 525.2 points.
- ORKA has been more active in the news (15 items in the past 4 weeks vs 5 for BMRA).
- ORKA has more recent analyst coverage (11 ratings vs 0 for BMRA).
- Company
- Biomerica Inc.
- Oruka Therapeutics Inc.
- Price
- $2.18-0.91%
- $62.54-8.87%
- Market cap
- $6.8M
- $3.10B
- 1M return
- -0.91%
- +23.87%
- 1Y return
- -42.33%
- +482.85%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 5
- 15
- Recent ratings
- 0
- 11
Biomerica Inc.
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Latest BMRA
- Biomerica's inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026
- Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway
- Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
- Biomerica Reports Third Quarter Fiscal 2026 Financial Results
- SEC Form 10-Q filed by Biomerica Inc.
- Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe
- Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain
- SEC Form S-8 filed by Biomerica Inc.
- Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy
- Vietnam Approves Biomerica's EZ Detect™ for Nationwide Distribution
Latest ORKA
- Chief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $319,384 worth of shares (5,000 units at $63.88) as part of a pre-agreed trading plan (SEC Form 4)
- Oruka Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Oruka Therapeutics Inc.
- Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
- SEC Form 424B5 filed by Oruka Therapeutics Inc.
- SEC Form 424B5 filed by Oruka Therapeutics Inc.
- Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
- Oruka Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
- Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026